FLS (FLS)

$10.7B
Market Cap
32.0
P/E Ratio
1.34
Beta
1.04%
Dividend Yield
Piotroski 7/9Altman Z 4.4 SafeBeneish M -2.60 CleanROIC−WACC -0.6%

Quantitative Summary

Deterministic

Financial health metrics are strong: Piotroski 7/9, Altman Z 4.4 (above 3.0 safe zone threshold).

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The capital efficiency profile reveals a company generating an ROIC of 11.3%, which sits comfortably above typical cost of equity thresholds, indicating value creation potential despite modest revenue expansion at just 3.8% year-over-year. The DuPont decomposition underscores that this return on equity of 15.4% is driven primarily by leverage rather than operational intensity; the 2.53x equity multiplier amplifies returns while the asset turnover ratio remains constrained at 0.83x, suggesting capital-intensive operations or slow inventory cycles relative to sales. Financial integrity appears robust with a Piotroski F-Score of 7/9 and a Beneish M-Score of -2.60, signaling strong fundamentals and low likelihood of earnings manipulation according to standard screening metrics.

Valuation multiples currently trade at a premium, with the P/E ratio expanding to 32.0x, which demands confirmation that future growth will materially outpace historical averages or sector peers to justify this spread. While the DCF model implies an intrinsic fair value of $83, the market price must be weighed against the assumption embedded in that valuation regarding implied long-term growth rates and terminal multiples; a 15% ROE supported by moderate margins may not sustain such high multiple expansion if macroeconomic headwinds compress operating leverage. The disconnect between current pricing and fundamental earnings generation suggests investors are anticipating significant margin improvement or acceleration in asset efficiency beyond the reported net margin of 7.3%.

Risk assessment highlights divergent signals regarding ownership structure, as insider activity over the last ninety days shows $978,359 in net selling, which often precedes broader market skepticism about near-term catalysts despite the company's clean financial scores. This divergence between strong Piotroski fundamentals and active principal reduction warrants close monitoring of upcoming earnings to determine if management views current valuation levels as appropriate or excessive relative to the 11.3% ROIC generation capability.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →9.9%11.9%13.9%
2%$74$57$46
3%$84$62$49
4%$96$69$53

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=11.9%, terminal growth 3%. Fair value $62 (+0.0%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

7/9
Piotroski F-Score
Strong — high operational efficiency and profitability signals
4.4
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.
-2.60
Beneish M-Score
Below threshold — no statistical earnings quality concern per Beneish model. Threshold: <-2.22 = below threshold.

Profitability & Value Creation

33.4%
Gross Margin
7.3%
Net Margin
11.3%
ROIC
11.9%
WACC
ROIC − WACC Spread: -0.6%— Negative spread.
+3.8%
Revenue Growth (YoY)
+22.4%
Earnings Growth (YoY)
435.0M
Free Cash Flow
25%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

DuPont Analysis — ROE Decomposition

Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.

7.3%
Net Profit Margin
NI ÷ Revenue
×
0.83x
Asset Turnover
Revenue ÷ Assets
×
2.53x
Equity Multiplier
Assets ÷ Equity
=
15.4%
Return on Equity
Balanced ROE composition across margins, turnover, and leverage.

Balance Sheet Health

1.53x
Debt / Equity
2.03x
Current Ratio
7.8x
Interest Coverage
1.1x
Net Debt / EBITDA
3.78%
FCF Yield
698.6M
EBITDA

Insider Activity (Last 90 Days)

Net Insider Flow
$-978,359
Net Selling
0
Buy Transactions
2
Sale Transactions
2026-03-02DUHON LAMAR L.Sold 1/8 qtrsOther7,241 shares
2026-03-02HUDSON SUSAN CLAIRESold 1/8 qtrsOther5,469 shares
2026-03-02BOUKALIK BRIANOther3,057 shares
2026-03-02SCHWETZ AMY B.Sold 1/8 qtrsOther14,210 shares
2026-03-02ROWE ROBERT SCOTTSold 2/8 qtrsOther41,564 shares

Open-market buys vs sells by company insiders. Source: yfinance.

Earnings Surprise History

Q4
✓ Beat
Est: $0.60
Act: $0.62
+3.0%
Q3
✓ Beat
Est: $0.78
Act: $0.91
+16.7%
Q2
✓ Beat
Est: $0.80
Act: $0.90
+13.2%
Q1
✓ Beat
Est: $0.94
Act: $1.11
+18.4%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

18.0
Forward P/E
PEG Ratio
4.89
Price/Book
2M
Avg Volume
$92.41
52W High
$39.85
52W Low
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$624M
Tracked Passive Exposure
8
ETFs Holding FLS
0.11%
Avg Weight in ETFs
$575B
Total ETF AUM

When investors buy or sell ETFs like MDYG or SPMD, the fund manager is mechanically forced to buy or sell FLS shares regardless of FLS's individual fundamentals. We estimate $624M of passive capital is structurally linked to FLS through 8 tracked ETFs. Passive flows have a limited but growing influence on FLS's daily trading dynamics.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in FLS to visualize passive redemption contagion across ETFs and collateral stocks.

FLS Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
FLSEpicenterVBETFVYMETFVXFETFFLEXMed RiskFTILow RiskTWLOLow RiskCWLow RiskNVTLow Risk
FLS Price Drop (%)0

If FLS (FLS) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies FLEX LTD (FLEX) as the most exposed collateral stock, sharing 2 ETFs with FLS. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 17 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

FLS Ownership Dynamics

Ticker
FLS

Float lock-up computed from 19 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

FLS Capital Efficiency

How efficiently does FLS convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$435M
EBITDA
$699M
FCF Conversion
62%
Reinvestment Rate
38%
62% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
11.3%
ROIC − WACC Spread
-0.6%

FLS converts 62% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. However, the ROIC-WACC spread is negative (-0.6%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Fails-to-Deliver (FTD) History

SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.

DateFailed SharesClose PriceNotional Value
2026-05-07789$73.38$57,896.82
2026-05-059,183$70.41$646,575.03
2026-05-0410,001$71.65$716,571.65
2026-04-291,129$85.06$96,032.74
2026-04-277,907$83.22$658,020.54
2026-04-212,172$83.41$181,166.52
2026-04-02204$75.40$15,381.6
2026-03-2648,446$76.59$3.7M
2026-03-24647$74.26$48,046.22
2026-03-23106$71.40$7,568.4
2026-03-17163$73.65$12,004.95
2026-03-0493$83.46$7,761.78
2026-02-2388,268$88.94$7.9M
2026-02-2041$88.21$3,616.61
2026-02-1275$86.54$6,490.5
2026-02-06100$78.98$7,898
2026-01-299$76.90$692.1
2026-01-235,854$78.60$460,124.4
2026-01-225,854$77.47$453,509.38
2026-01-215,854$75.90$444,318.6
2026-01-20443$77.17$34,186.31
2025-12-222,851$71.06$202,592.06
2025-12-16148$71.82$10,629.36
2025-11-19635$65.54$41,617.9
2025-11-1712,200$67.16$819,352
2025-11-1412,200$68.00$829,600
2025-11-1312,200$69.95$853,390
2025-11-1013$69.24$900.12
2025-10-3114,816$67.35$997,857.6
2025-10-15292$51.25$14,965

Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.

Compare FLS to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.